SSAS

Cosco Shipping Enhances Safety with Iridium GMDSS

Retrieved on: 
Tuesday, March 12, 2024
Iridium Communications, COSCO Shipping, IRDM, Transport, Arctic Ocean, SSAS, Roll-on/roll-off, Ship Security Alert System, Ship, Safety, Telecom, LRIT, Optimism, GMDSS, CSSC, Shipbuilding

Iridium GMDSS now provides unmatched support for Cosco Tengfei's mission with its truly global coverage, distress alert, safety voice, maritime safety information, and cost-effective implementation and operation.

Key Points: 
  • Iridium GMDSS now provides unmatched support for Cosco Tengfei's mission with its truly global coverage, distress alert, safety voice, maritime safety information, and cost-effective implementation and operation.
  • Mr. Xiaofeng Guo, Director of Telecom and Navigation Department at CSSC, expressed optimism about the deployment of Iridium GMDSS on the Cosco Tengfei, "I am glad to witness the moment of the first Iridium GMDSS system deployment on a CSSC vessel, the 'COSCO TENGFEI.'
  • Cosco Shipping is the world's largest shipping fleet, and CSSC understands the value proposition that Iridium GMDSS delivers."
  • Cosco Shipping's commitment to safety, supported by the deployment of Iridium GMDSS on the Cosco Tengfei, underscores their dedication to ensuring the well-being of their crew, vessels, and cargo in an ever-changing and challenging maritime environment.

Cosco Shipping Enhances Safety with Iridium GMDSS

Retrieved on: 
Tuesday, March 12, 2024
Iridium Communications, COSCO Shipping, IRDM, Transport, Arctic Ocean, SSAS, Roll-on/roll-off, Ship Security Alert System, Ship, Safety, Telecom, LRIT, Optimism, GMDSS, CSSC, Shipbuilding

Iridium GMDSS now provides unmatched support for Cosco Tengfei's mission with its truly global coverage, distress alert, safety voice, maritime safety information, and cost-effective implementation and operation.

Key Points: 
  • Iridium GMDSS now provides unmatched support for Cosco Tengfei's mission with its truly global coverage, distress alert, safety voice, maritime safety information, and cost-effective implementation and operation.
  • Mr. Xiaofeng Guo, Director of Telecom and Navigation Department at CSSC, expressed optimism about the deployment of Iridium GMDSS on the Cosco Tengfei, "I am glad to witness the moment of the first Iridium GMDSS system deployment on a CSSC vessel, the 'COSCO TENGFEI.'
  • Cosco Shipping is the world's largest shipping fleet, and CSSC understands the value proposition that Iridium GMDSS delivers."
  • Cosco Shipping's commitment to safety, supported by the deployment of Iridium GMDSS on the Cosco Tengfei, underscores their dedication to ensuring the well-being of their crew, vessels, and cargo in an ever-changing and challenging maritime environment.

Microsoft and Octopai to Co-Sell Leading Innovative Data Management Integration

Retrieved on: 
Monday, October 30, 2023
Data Analytics, Data Management, Professional Services, Technology, Software, Knowledge, Cloud, Self-service, BI, SSRS, Migration, Azure, Microsoft, SSIS, Data management, Risk management, Partnership, MACC, Microsoft Power BI, Microsoft Azure, SSAS, Democratization, IP, Metadata, MySQL, Video game

Upon achieving this Co-Sell Incentivized status, Octopai emerges as a preferred solution in the Microsoft Azure Marketplace for metadata management.

Key Points: 
  • Upon achieving this Co-Sell Incentivized status, Octopai emerges as a preferred solution in the Microsoft Azure Marketplace for metadata management.
  • This collaboration with Microsoft further amplifies its capabilities, granting users a more cohesive and integrated data management experience with Microsoft's suite of cloud, data warehouse, data movement and BI products.
  • These time savings are particularly impactful in areas like ad-hoc analysis, impact analysis, training, vendor data management, and production troubleshooting.
  • To see Octopai in action, request a brief product demonstration of the seamless and efficient integration between Microsoft and Octopai here .

The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve

Retrieved on: 
Friday, June 2, 2023
Learning, Indigenous Services Canada, Partnership, Student, Education, Life, Assembly, Culture, Truth and Reconciliation Commission of Canada, SSAS, Truth, Policy, ISC, Assembly of First Nations, Language, First, School, Investment, AFN, Indigenous self-government in Canada, Knowledge, Nursing, Tourism, Tutoring, First Nations

Working in partnership, the Assembly of First Nations (AFN) and Indigenous Services Canada (ISC) continue to take significant steps toward improving education infrastructure for First Nations communities across Canada.

Key Points: 
  • Working in partnership, the Assembly of First Nations (AFN) and Indigenous Services Canada (ISC) continue to take significant steps toward improving education infrastructure for First Nations communities across Canada.
  • supports lifelong learning as First Nations adults are included in new school designs that supports education upgrading and language learning.
  • These are the best school standards in Canada, and First Nations continue to be a global leader in Indigenous-led school standards.
  • The Government of Canada has committed $2.34 billion up to 2024–2025 in First Nations school facilities, which includes $860.5 million from Budget 2021.

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

Retrieved on: 
Thursday, January 12, 2023
Endometriosis, Prostate cancer, CPP, GEP-NET, Quality of life, Safety, SSAS, Octreotide, SSA, Injection, Patient, Degenerative disease, Rare, Puberty, Breast cancer, Health, Endocrinology, Pharmaceutical industry, Debiopharm, Acromegaly

LAUSANNE, Switzerland, Jan. 12, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced that the first patient was dosed with Debio 4126, a 3-month extended-release formulation of octreotide, in their open-label, non-randomized, single-arm, multicenter phase 1b study (Debio 4126-102). The study is composed of two patient cohorts – 1 group of patients with acromegaly and 1 group with functioning GEP-NETs Patients will receive 4 injections of Debio 4126 for a total treatment duration of 48 weeks.

Key Points: 
  • - Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into an improved quality of life and less time spent with medical visits.
  • One of them (study Debio 4126-102) is a phase 1b study in patients with acromegaly or GEP-NETs.
  • If successful, Debio 4126 will equip healthcare professionals with a new, more convenient option for treating acromegalic and GEP/NET patients.
  • "Going into this 2-year long phase 1b trial, we look forward to ascertaining the benefits of this extended-release formulation.

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

Retrieved on: 
Thursday, January 12, 2023
Endometriosis, Prostate cancer, CPP, GEP-NET, Quality of life, Safety, SSAS, Octreotide, SSA, Injection, Patient, Degenerative disease, Rare, Puberty, Breast cancer, Health, Endocrinology, Pharmaceutical industry, Debiopharm, Acromegaly

LAUSANNE, Switzerland, Jan. 12, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced that the first patient was dosed with Debio 4126, a 3-month extended-release formulation of octreotide, in their open-label, non-randomized, single-arm, multicenter phase 1b study (Debio 4126-102). The study is composed of two patient cohorts – 1 group of patients with acromegaly and 1 group with functioning GEP-NETs Patients will receive 4 injections of Debio 4126 for a total treatment duration of 48 weeks.

Key Points: 
  • - Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into an improved quality of life and less time spent with medical visits.
  • One of them (study Debio 4126-102) is a phase 1b study in patients with acromegaly or GEP-NETs.
  • If successful, Debio 4126 will equip healthcare professionals with a new, more convenient option for treating acromegalic and GEP/NET patients.
  • "Going into this 2-year long phase 1b trial, we look forward to ascertaining the benefits of this extended-release formulation.

COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors

Retrieved on: 
Monday, December 19, 2022
NET, Octreotide, EC, Somatostatin, CHMP, Carcinoid syndrome, European Medicines Agency, Acromegaly, Royal commission, Person, European Directive on Traditional Herbal Medicinal Products, SSAS, Patient, Committee, Degenerative disease, European Commission, Maintenance, FDA, Union, Wilms' tumor, Committee for Medicinal Products for Human Use, EMA, COMP, Pharmaceutical industry, EU

Orphan designation in the European Union (EU) is granted by the European Commission (EC) within 30 days of a positive opinion being issued by the COMP.

Key Points: 
  • Orphan designation in the European Union (EU) is granted by the European Commission (EC) within 30 days of a positive opinion being issued by the COMP.
  • This designation provides certain regulatory and financial incentives including but not limited to product market exclusivity for ten years in the EU following regulatory approval.
  • The granting of the orphan designation in the treatment of carcinoid syndrome follows the COMP positive opinion in October 2022 recommending that the orphan designation of Mycapssa® in the treatment of acromegaly in the EU is maintained following approval of the marketing authorisation for the product.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: “The COMP positive opinion on the recommendation to grant orphan designation for Mycapssa® in the treatment of carcinoid syndrome represents a significant development for patients with carcinoid syndrome associated with neuroendocrine tumors in Europe.

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

Retrieved on: 
Monday, November 14, 2022
Marketing, LNTH, NORTH, New Drug Application, Cancer, NET, Safety, Security (finance), Somatostatin, Food and Drug Administration, Vii, Growth, Hart–Scott–Rodino Antitrust Improvements Act, Hospital, Xi, Actinium-225, University Health Network, NDA, Ix, FDA, Failure, MCRPC, Adjustment, UHN, Drug Quality and Security Act, SSAS, EPS, Food, SPLASH, PSMA, Prostate cancer, Intelligence, Standard of care, Radiopharmaceutical, Risk, Patient, Pharmaceutical industry, Medical imaging, Medical device

NORTH BILLERICA, Mass. and INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (”Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights1 to POINT’s PNT2002 and PNT2003 product candidates.

Key Points: 
  • Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003.
  • The agreements expand Lantheus radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus prostate cancer franchise.
  • Under the agreements, POINT will fund and complete its Phase 3 SPLASH trial for PNT2002, following which Lantheus will file the New Drug Application (NDA) in collaboration with POINT.
  • Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories1, for PNT2002 and PNT2003 with cash on Lantheus balance sheet and committed financing.

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

Retrieved on: 
Monday, November 14, 2022
Marketing, LNTH, NORTH, New Drug Application, Cancer, NET, Safety, Security (finance), Somatostatin, Food and Drug Administration, Vii, Growth, Hart–Scott–Rodino Antitrust Improvements Act, Hospital, Xi, Actinium-225, University Health Network, NDA, Ix, FDA, Failure, MCRPC, Adjustment, UHN, Clarivate, Drug Quality and Security Act, SSAS, EPS, Food, SPLASH, PSMA, Prostate cancer, Intelligence, Standard of care, Radiopharmaceutical, Risk, Patient, Pharmaceutical industry, Medical imaging, Medical device

NORTH BILLERICA, Mass. and INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (”Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights1 to POINT’s PNT2002 and PNT2003 product candidates.

Key Points: 
  • Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003.
  • The agreements expand Lantheus radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus prostate cancer franchise.
  • Under the agreements, POINT will fund and complete its Phase 3 SPLASH trial for PNT2002, following which Lantheus will file the New Drug Application (NDA) in collaboration with POINT.
  • Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories1, for PNT2002 and PNT2003 with cash on Lantheus balance sheet and committed financing.

Liquidnet Advances Electronification of Primary Market Workflow With Live Deals

Retrieved on: 
Monday, November 7, 2022
Networks, Data Analytics, Finance, Banking, Data Management, Professional Services, Technology, Fintech, Janus, EMEA, Warsaw Stock Exchange, Financial Conduct Authority, Central bank, London Stock Exchange, SIX Swiss Exchange, Financial Sector Conduct Authority (South Africa), Australian Securities and Investments Commission, SSAS, TP, Central Bank of Ireland, Securities and Futures Commission, REDI (Execution Management System), Group, EMS, Primary market, London, Finance, Financial Services Agency, Market, AFSL, Intelligence, Canadian Investor Protection Fund, Data Analytics Acceleration Library, View, Monetary Authority of Singapore, CMS, CMSL, Money, Investment Industry Regulatory Organization of Canada, CRD, Janus Henderson, Investment Commission, Efficiency, Security (finance), Liquidnet

Mark Russell, Global Head of Fixed Income at Liquidnet, said: We are delighted to deliver on our promise; a primary market workflow that brings real efficiency to the live deals in the market.

Key Points: 
  • Mark Russell, Global Head of Fixed Income at Liquidnet, said: We are delighted to deliver on our promise; a primary market workflow that brings real efficiency to the live deals in the market.
  • Jonathan Gray, Head of Primary Markets, EMEA, added: Weve been on this electronification journey alongside the buy side for a number of years now.
  • With these live deals, we have now proven that it all works, that we got there.
  • The seamless completion of live deals through the Liquidnet platform is a major step forward.